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 Clinically relevant responses were observed at 50-100mg/day, Caverage 41-
129ng/ml), with mild EPS emerging at 96ng/ml (In AD, severe EPS emerged at 
60ng/ml) 
 Caudate occupancy was 44-59% in 3 patients imaged at Caverage 41-70ng/ml) (In 
AD, caudate occupancy 58-74% the same Caverage range) 
 Further investigation of age and diagnosis-specific threshold sensitivities for EPS is 
warranted and therapeutic drug monitoring studies are a potentially feasible future 
approach 
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Abstract  
Objective: Antipsychotic drug sensitivity in very late-onset schizophrenia-like psychosis 
(VLOSLP) is well documented, but poorly understood. This study aimed to investigate blood 
drug concentration, D2/3 receptor occupancy, and outcome in VLOSLP during open 
amisulpride prescribing, and compare this with Alzheimer’s disease (AD). 
Methods: Blood drug concentration, symptoms (suspiciousness, unusual thought content, 
hallucinations) and extrapyramidal side-effects (EPS), were serially assessed during dose 
titration. [18F]fallypride imaging was used to estimate D2/3 receptor occupancy. Average 
steady state drug concentration (Caverage) was estimated by incorporating pharmacokinetic 
(PK) data into an existing population PK model (25 AD participants, 20 healthy older people).   
Results: Eight patients (original target 20) were recruited (6 women; 76  6 years), 6 of whom 
complied with treatment: blood samples were obtained from 5; and paired imaging data from 
3 participants. Mean+-SD reduction in symptoms was 74 ± 12% (Caverage 92.5+-39.4ng/ml). 
Mild EPS (Simpson Angus Scale, SAS, score of 4), which did not lead to treatment withdrawal, 
emerged at Caverage 96ng/ml (in AD, severe EPS, SAS score of 15, emerged at 60ng/ml). In 
3 participants, imaged at an optimal dose of 50mg/day (Caverage 41-70ng/ml), caudate 
occupancy was 44-59% (compared to 58-74% in AD).  
Conclusions: Despite small sample size, our findings are highly relevant and suggest that, 
similar to AD, 50mg/day amisulpride is associated with clinically relevant responses and 
occupancies >40% in VLOSLP. Although the two groups overlap in terms of minimum clinically 
effective dose, the AD group were more susceptible to emergent EPS. It is unclear, due to 
small sample size, whether these differences are accounted for by a steeper concentration-
occupancy curve in AD. Therapeutic drug monitoring studies of amisulpride offer a potentially 
feasible approach to future investigation of age and disease-specific threshold sensitivities for 
EPS. Alongside this, research should focus on understanding and addressing barriers to 
service engagement in VLOSLP 
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Introduction 
Older people with very late- (>60 years) onset schizophrenia-like psychosis (VLOSLP) 
(Howard et al., 2000), are amongst the most challenging mental health patient groups to 
engage and treat (Sin Fai Lam et al., 2016). Typically presenting with systematised 
persecutory beliefs, they generally lack insight into their illness or the potential benefits of 
treatment (Howard et al., 1994) and are unwilling to engage with older adult mental health 
teams (Sin Fai Lam et al., 2016). In those who initially accept antipsychotic drug treatment, 
heightened susceptibility to extrapyramidal side effects (Howard et al., 2000; Uchida et al., 
2008) only increases the likelihood of non-compliance and subsequent disengagement from 
treatment and follow-up (Reeves et al., 2002; Hudson et al., 2004).  
The mechanisms underlying antipsychotic drug sensitivity in VLOSLP are poorly understood, 
as research in older people with schizophrenia rarely distinguishes between patients on the 
basis of age of illness onset (Jeste and Maglione, 2013; Uchida et al., 2008), and the focus of 
research is increasingly directed towards those with dementia, who are at greatest risk of 
antipsychotic related morbidity and mortality (Jennum et al., 2015; Jeste et al., 2008; Maust 
et al., 2015; Howard et al., 2016). Age-related changes in pharmacokinetics (PK), which 
reduce drug clearance, contribute to side effects by increasing blood drug concentration for a 
given dose (Feng et al., 2008; Uchida et al., 2009b). However this effect is not consistent 
across all antipsychotics (Bigos et al., 2008) and fails to account for the heightened sensitivity 
of people with dementia and VLOSLP to EPS (Howard et al., 2000) compared to people with 
an earlier onset of schizophrenia. 
Since the therapeutic window of striatal dopamine D2/3 receptor occupancy was first 
described for antipsychotic drugs (Farde et al., 1992; Kapur et al., 1995), positron emission 
tomography (PET) has been used to guide safe and effective prescribing in young people 
(Uchida et al., 2011; Sparshatt et al., 2009; Lako et al., 2013). In contrast, there is a relative 
paucity of imaging data in older clinical populations. Occupancy studies carried out in older 
patients with schizophrenia prescribed risperidone and/or olanzapine, have consistently 
reported EPS at lower than anticipated threshold occupancies (Uchida et al., 2009a; Graff-
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Guerrero et al., 2015; Uchida et al., 2014). These data suggest that age-related 
pharmacodynamic changes, which increase functional outcomes for a given D2/3 receptor 
occupancy, contribute to antipsychotic drug sensitivity.   
We have recently used an adapted [18F]fallypride imaging protocol (Clark-Papasavas et al., 
2014; Dunn et al., 2013) to investigate the relationship between dose, blood drug 
concentration and central D2/3 receptor occupancy in older patients with Alzheimer’s disease 
(AD)  and VLOSLP who were prescribed amisulpride off label to treat psychosis symptoms, 
as part of an open treatment study. Amisulpride dose-concentration (Reeves et al., 2016), and 
concentration-occupancy profiles across a 25-75mg/day dose range have been previously 
described in the AD group (Reeves et al., 2017). Low amisulpride blood concentrations (9-
109ng/ml), which in all but one individual were below the recommended optimal therapeutic 
range (100-319 ng/ml) (Hiemke et al., 2011; Sparshatt et al., 2009) for the treatment of positive 
symptoms in schizophrenia, were associated with high D2/3 receptor occupancies (43-84% in 
the caudate), symptomatic improvement and emergent EPS (Reeves et al., 2017).  
Our findings suggest that increased occupancy for a given blood drug concentration plays a 
key role in antipsychotic drug sensitivity in older people with AD, and implicate the blood brain 
barrier, which controls central drug access. However, the relative importance of the 
contribution of age and AD-specific changes to increased D2/3 receptor occupancy is unclear. 
The current study involves the analysis of data from VLOSLP participants in the study, and 
aims to explore amisulpride dose-concentration-occupancy relationships and compare this 
with the situation in AD.  
Methods 
Sample 
Patients with VLOSLP were recruited from the South London and Maudsley NHS Foundation 
Trust immediately prior to commencing amisulpride treatment. Participants were included on 
the basis of meeting diagnostic criteria for VLOSLP (Howard et al., 2000), and having no 
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previous history of psychotic illness (prior to 60 years), traumatic brain injury, epilepsy, 
significant cardiorespiratory disease, needle phobia, any contraindication to amisulpride, or 
features suggestive of dementia. Patients were excluded if antipsychotic medication had been 
prescribed in the past 2 weeks (6 weeks if prescribed depot medication), or if unable to give 
informed consent. The study was approved by Berkshire Research Ethics Committee (REC 
reference 11/SC/0486).  
Additional data sources 
In order to estimate average steady state concentration of amisulpride across the 24 hour 
dosage interval, PK data from patients with VLOSLP were combined with PK data from: 
(i) AD participants from the open study, which included 41 blood samples taken from 
25 participants during steady state amisulpride treatment with 25-75mg/day (8 
(32%) men; 82 +-6.6 years) (Reeves et al., 2016).  
(ii) A richly sampled phase I study carried out in healthy older people, each sampled 
14 times over 72 hours following a single oral 50mg amisulpride dose (10 (50%) 
men; age = 68.7 ± 4.1 years) (Hamon-Vilcot et al., 1998). Venous blood samples 
(n=280) were obtained from 20 healthy older participants. Amisulpride (racemate) 
concentrations were determined using a validated HPLC (high performance liquid 
chromatography) method (detection limit 0.5 ng/ml).  
Baseline and Follow up Assessments 
Clinical assessments were carried out at baseline and every 14  7 days during dose titration, 
and included i) Psychotic symptoms were rated using the summed total score of 3 items from 
the  Brief Psychiatric Rating Scale (BPRS) which are most relevant for very late-onset SLP: 
unusual thought content, suspiciousness, and hallucinations (Overall, 1988). Each item is 
scored on a 7 point scale, where 1 indicates ‘symptom not present’ and 7 ‘extremely severe’ 
(ii) EPS were indexed as present or absence by scores of 3 or more on the clinician-rated 
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Simpson-Angus Scale (SAS) (3-5=mild; 6 or more =severe) (Simpson and Angus, 1970) 
and/or 2 or more on the  Barnes Akathisia scale (Barnes, 1989).  
Amisulpride dose titration and blood sampling 
Patients commenced amisulpride treatment at 50mg/day and were followed up every 14+-7 
days, until an optimum dose was achieved (defined as >25% reduction in BPRS summed 3 
item total scores). Compliance with medication (pill counts, discussion with a carer), 
concomitant medication and clinical outcome (symptom ratings, side effects) were recorded 
at each visit. Amisulpride venous blood concentration was measured prior to each dose 
increase, with the timing of blood samples coinciding with follow-up assessments and/or 
imaging. Blood samples were analysed in a secure, CPA accredited laboratory (Clinical 
Toxicology Unit, Kings College Hospital). Amisulpride (racemate) blood concentrations were 
determined using validated LC-MS/MS (liquid chromatography with tandem mass 
spectrometry) method, with a detection limit of 9ng/ml. Prolactin concentration was measured 
using chemiluminescence immune assay (Siemens Advia Centaur XP assay), with a detection 
limit of 6.4 mIU/L (0.29 ng/ml). 
PET Procedure 
Participants were scanned on a GE (GE Healthcare, Hatfield, UK) VCT Discovery PET-CT 
camera (FWHM 5mm), at St Thomas’ Hospital PET Centre, using an interrupted [18F]fallypride 
imaging protocol adapted specifically for use in older patients (Clark-Papasavas et al., 2014; 
Dunn et al., 2013) . [18F]fallypride was administered via a single bolus intravenous injection of 
250MBq. Each scan consisted of three 20-minute dynamic scans (3D mode, each preceded 
by low dose CT for attenuation correction) at baseline (0-20, 70-90, 220-240 minutes) and 
post-treatment (0-20, 40-60, 130-150 minutes); shorter post-treatment scan duration reflecting 
the fact that amisulpride occupancy of D2/3 receptors reduces the time required for 
[18F]fallypride to achieve a transient equilibrium (Kegeles et al., 2008; Vernaleken et al., 2011). 
[18F]fallypride binding potential BPND (Innis et al., 2007) was quantified using a simplified 
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reference tissue model with cerebellar reference region (Lammertsma and Hume, 1996).  
Preprocessing was performed using statistical parametric mapping version 8 
(www.fil.ion.ucl.ac.uk/spm) and all other analyses using Matlab (www.mathworks.com). Non-
attenuation corrected, 3 dimensional iteratively reconstructed PET scans (GE ‘VuePoint’) were 
used for frame-by-frame realignment. Transformations were applied to attenuation corrected, 
filtered back projected PET images which were used for quantification, and attenuation 
corrected-VuePoint PET images used for warping atlases. The cerebellum was defined using 
the Automated Anatomical Labeling atlas (Tzourio-Mazoyer et al., 2002) and regions of 
interest (caudate, putamen, thalamus) were defined using the Tziortzi atlas (Tziortzi et al., 
2011). Atlases were warped to subject space via a [18F]fallypride template in standard  space 
(Dunn et al., 2013). Percentage reduction in BPND between pre (BPPRE) and post (BPPOST) 
treatment scans was used to estimate occupancy, as follows: [(BPPRE-BPPOST)/BPPRE]*100.  
Statistical analysis 
Demographic and clinical data were described using SPSS (version 22.0). Values are shown 
as mean ± SD. The original recruitment target was 20 patients, to allow direct comparison with 
AD patients and to control for age. Blood drug concentration is highly dependent on the timing 
of blood sampling and, to control for this, average steady state drug concentration across the 
dosage interval (Caverage) was estimated by incorporating PK data into a previously 
described, oral 2 compartment population PK model for amisulpride, developed from 25 AD 
and 20 healthy older participants (Reeves et al., 2016) (see additional data sources). The 
model described 5 parameters (i) an absorption constant (ka), (ii) a central compartment (V1), 
(iii) a peripheral compartment (V2), (iv) an inter-compartmental distribution constant (Q), (v) 
an elimination constant (CL), which includes renal and systemic clearance. Initial parameter 
estimates were based on previously described values (Reeves et al., 2016), and incorporated 
covariate effects (age and a scaling factor based on standard 70kg body weight) on CL.  
The population approach uses nonlinear mixed effects (NLME) modelling to examine dose-
concentration relationships, identify sources of variability and make predictions for a typical 
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person in the population of interest (Ette et al., 2004; Duffull et al., 2011). NLME modelling, 
implemented using Monolix software (version 4.33; www.lixoft.eu), simultaneously estimates 
fixed effects (value for the average subject in the sample), and random effects (inter-individual 
variability, IIV) variance for parameters describing dose-concentration relationships and 
residual errors variance (unexplained variability, reflecting system noise, dosage history errors 
and/or model misspecifications). IIV was estimated using an exponential model Pi = PTV × eηp 
where Pi is the parameter estimate for the ith individual, and PTV is the typical value for the 
parameter at the population level. Random effects between ith individual and population 
parameter values (eta, ηp), was assumed to be normally distributed (mean of 0, variance ωη2).  
As described previously (Reeves et al., 2016), residual error was modelled separately for 
healthy older people and participants in the clinical study, to account for inter-study 
differences; and was described using a proportional residual error model (yij = ŷij (1+ εij), where 
yij and ŷij represents the jth observed concentration of the ith subject and corresponding model-
predicted concentration; and εij was assumed to be normally distributed (mean of 0, variance 
σ2.). The model was evaluated using goodness-of-fit criteria, including diagnostic scatter plots, 
visual predictive checks, degree of shrinkage model precision, and likelihood ratio. Individual 
parameter estimates from the model included Caverage. 
Results 
VLOSLP sample characteristics  
Eight patients (6 women; age 76  6 years) were recruited, 2 of whom were withdrawn due to 
lack of compliance with study procedures. Demographic and clinical data are presented in 
Table 1. In the 6 patients who complied with treatment, baseline BPRS 3 item total score was 
18.3 +- 2.2 (6.5 +- 0.6 unusual thought content; 6.8 +- 0.4 suspiciousness; 5.0 +- 2.0 
hallucinations). Following treatment with 50-100mg/day amisulpride, there was a 74 ± 12 % 
reduction in BPRS 3 item total scores (76 ± 15%, unusual thought content; 68% ± 20%, 
suspiciousness; and 69% ± 34%, hallucinations), with complete resolution of symptoms 
(BPRS score of 3) in 2 participants (Table 1). Mild EPS which did not lead to treatment 
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discontinuation (SAS scores 3, and 4), emerged in 2 participants; and 1 patient developed 
hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion, 
(SIADH), which led to withdrawal from the study.  
Pharmacokinetic, prolactin, imaging and clinical outcome data 
Mean +-SD amisulpride blood concentration (n=5) was 69.5+-34.9 ng/ml; and corresponding 
PRL concentration (5.6+-1.5 pre-treatment), was 95+-41ng/ml (15+-3 hours post dose) after 
21-191 days of treatment (PRL 88+-72ng/ml in AD). When PK data were incorporated into the 
existing PK model (Table 2), parameters estimates were consistent with those previously 
described (Reeves et al., 2016), and estimated Caverage was 92.5+-39.4 ng/ml (range 41.5-
129ng/ml). Mild EPS, (SAS score of 4), emerged at a lower threshold Caverage of 96ng/ml 
(75mg/day), and one participant developed akathisia (Barnes score of 3) at 129ng/ml. In 
previously described AD participants, severe EPS (SAS scores of 11, 15 and 16) emerged at 
Caverage of 60, 61 and 62 ng/ml in 3 participants (Reeves et al., 2017).  Figure 1 shows 
Caverage, plotted against SAS scores for a) AD and b) VLOSLP groups, separated on the 
basis of mild (scores of 3-5) and severe (scores of 6 or above) EPS. 
Technical issues meant that it was only possible to carry out 5 pre-treatment scans (mean+-
SD binding potential, BPPRE: 16.31  1.32, caudate; 20.58  2.0, putamen;1.49  0.17, 
thalamus), and of 5 post-treatment scans were attempted, only 3 produced data of sufficient 
quality due to technical issues (n=1) or tolerability (n=1) (mean+-SD binding potential, BPPOST: 
7.59  1.56, caudate; 11.95  3.94, putamen; 0.72  0.25, thalamus). Caverage and 
corresponding caudate occupancy in 3 participants with paired imaging data, imaged at an 
optimum 50mg/day dose, was 41ng/ml (44%), 63ng/ml (51%) and 70ng/ml (59%). In AD, 
caudate occupancy ranged from 58-74% across Caverage 41-70ng/ml. Caverage, plotted 
against caudate occupancy is shown for VLOSLP and AD participants in Figure 2. 
Discussion 
This study aimed to characterise amisulpride dose-PK-occupancy relationships in VLOSLP, 
using an adapted imaging protocol. Carrying out imaging studies in older people is highly 
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challenging, particularly when combined with an active drug treatment, and participation 
requires a degree of insight and a level of engagement rarely achieved in people with VLOSLP 
(Howard et al., 1994; Sin Fai Lam et al., 2016).  As a consequence, recruitment and retention 
were poor and, in addition, technical issues meant that it was only possible to obtain a 
complete dataset in 3 participants. Heightened sensitivity to EPS is well documented in 
VLOSLP (Howard et al., 2000; Uchida et al., 2008; Jeste and Maglione, 2013) and open label 
trial data suggests that ~100mg/day (range 50-200mg/day) amisulpride is efficacious in 
VLOSLP (Psarros et al., 2009), compared to older patients with an earlier illness onset, who 
tolerate doses up to 400mg/day (Riedel et al., 2009). Our findings were consistent with this, 
as clinically relevant responses were observed in VLOSLP patients at 50-100mg/day, and 
correspondingly low blood drug concentrations. Small sample size meant that it was not 
possible to fully characterise the non-linear PK-occupancy curve in VLOSLP. However, our 
findings suggest that 50mg/day amisulpride is associated with occupancies which achieve the 
therapeutic window (>40%) required to treat positive symptoms in young adults with 
schizophrenia (Sparshatt et al., 2009).  
Occupancy data during low dose (50-100mg/day) amisulpride treatment is highly variable in 
young adults, ranging from below 10% (Martinot et al., 1996; Xiberas et al., 2001) to 40% (la 
Fougere et al., 2005; Meisenzahl et al., 2008) in the striatum. This is partly accounted for by 
methodological differences (tracer, imaging modality, timing of the scan in relation to dose, 
scan duration) (Meisenzahl et al., 2008), but also reflects the steeper gradient of the 
occupancy slope at low blood drug concentrations (Vernaleken et al., 2004).  Our findings 
suggest that, similar to AD, 50mg/day (Caverage (41-70ng/ml) was associated with 
occupancies at least as high as those observed in young adults (Bressan et al., 2003; Lako et 
al., 2013; Sparshatt et al., 2009). As discussed previously (Reeves et al, 2017), tracers with 
higher affinity (low dissociation constant) such as [18F]fallypride require higher concentrations 
of competing drug to displace them from receptor sites than those of lower affinity, leading to 
lower apparent occupancy (Seeman, 2011; Seeman, 2014; Seeman and Van Tol, 1995). In 
vivo, this is particularly problematic if there is insufficient imaging time for the tracer to achieve 
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equilibrium in the D2/3 rich striatum (Olsson and Farde, 2001; Xiberas et al., 2001; Vernaleken 
et al., 2011). Although sampling times for the current study were guided by previous post-
treatment [18F]fallypride protocols (Kegeles et al., 2008; Kessler et al., 2006), we cannot rule 
out the possibility that we have under-estimated the true extent of the differences between 
young adults previously studied and those with AD and VLOSLP.   
Previous imaging studies have estimated occupancy in (risperidone and/or olanzapine) 
treated older patients with schizophrenia, by comparing D2/3 receptor availability with a 
healthy older control group, and described a therapeutic window of occupancy (50-60%)  
compared to young adults (Graff-Guerrero et al., 2015; Uchida et al., 2014); findings that are 
not explained by differences in D2/3 receptor availability between ‘antipsychotic free’ patients 
and healthy older people (Nakajima et al., 2015). Importantly, the above studies observed no 
difference in concentration-occupancy relationships between young and older adults. 
It is possible that our finding of higher than anticipated occupancy in both AD and VLOSLP 
compared to young adults may reflect the unique properties of amisulpride (lower lipophilicity, 
poor blood brain barrier (BBB) penetration relative to other antipsychotics) (Natesan et al., 
2008), which make the drug a more sensitive tool with which to explore BBB integrity in older 
people. It will thus be important to use comparable methodology (drug, tracer, sampling times, 
method of analysis) in future studies. Other central mechanisms also need to be considered, 
as we cannot rule out the possibility that age and/or disease-specific changes in distribution 
and clearance of amisulpride within the central nervous system (Uchida et al., 2009b), and/or 
reduced competition due to lower endogenous dopamine levels (Volkow et al., 1994) in those 
of extreme age contributed to higher occupancies.  
Our findings suggest there is some overlap between AD and VLOSLP in terms of minimally 
clinically effective dose, but there are also clear differences in sensitivity to side effects, as 
severe EPS emerged in AD at very low threshold drug concentrations (60ng/ml). Differences 
between the two groups were not accounted for by variability in the timing of blood samples, 
as the PK model allowed estimation of average concentration across the dosage interval for 
each individual, accounting for the impact of age and body weight. It is tempting to speculate 
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that the exquisite sensitivity in AD is explained by higher occupancy for a given for a given 
amisulpride blood concentration, due to greater disruption in BBB integrity ( (Zeevi et al., 
2010). However, it is equally possible that the observed differences simply reflect the inherent 
variability in concentration-occupancy relationships, or that other confounding factors, such as 
age, gender, or concomitant medication explain the heightened susceptibility of older people 
with AD to side effects.   
Non-adherence is another potential source of error when attempting to estimate dose-PK-
response relationships. Although compliance was facilitated and closely monitored, tablet 
counts and self-report are not wholly reliable, (Blaschke et al., 2012) and may have contributed 
to inter-individual variability in parameter estimates, and residual error. The issue of diagnosis 
is important when psychosis is present in the context of a dementia, and careful screening 
was thus carried out to exclude patients with suspected Lewy Body Dementia, included 
dopamine transporter imaging where appropriate (McKeith et al., 1996). While we cannot 
completely rule out the possibility that Lewy body pathology may have contributed to the 
observed drug sensitivity in AD group, EPS are sufficiently explained by higher than 
anticipated occupancies which only exceeded the 60% threshold in the AD group.   
 
Conclusion 
Despite the limitations of the clinical dataset, this study indicates that target concentrations to 
treat psychosis in AD and VLOSLP overlap, and are lower than the currently recommended 
target range (100-320ng/ml), due to higher than anticipated central D2/3 receptor 
occupancies. Our preliminary findings also argue strongly for further investigation of disease-
specific differences in antipsychotic drug sensitivity, as the target therapeutic range for 
amisulpride is broader in VLOSLP, possibly due to differences in the PK-occupancy slope. 
However, these findings are preliminary and should be interpreted cautiously, given the limited 
sample size. In young adults, it has been shown that amisulpride blood drug concentration is 
a more sensitive predictor of EPS than D2/3 receptor occupancy (Sparshatt et al., 2009). 
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Given the challenges faced when attempting occupancy studies in older people, large scale 
amisulpride therapeutic drug monitoring studies offer a feasible, cost effective alternative 
approach, and one which will directly inform age- and disease-specific dose adjustments. 
Alongside this, research needs to be directed towards improving service engagement in 
people with VLOSLP.  
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Figure 1. Model estimated Caverage and extrapyramidal side effects 
Estimated average steady state amisulpride blood concentrations (Caverage) across a 25-
100mg dose titration range are plotted against corresponding Simpson Angus Scale scores, 
and separated on the basis of absent (white circle), mild (black and white circle) and severe 
(black circle) extrapyramidal side effects (EPS) in VLOSLP (left) AD (right). 
 
Figure 2. Caverage, D2/3 receptor occupancy and extrapyramidal side effects 
 
Caverage is plotted against corresponding D2/3 receptor occupancy in the caudate, for 3 
VLOSLP participants, none of whom experienced extrapyramidal side effects (EPS) (shown 
as a dot with outer circle); superimposed on data from AD participants, separated on the basis 
of presence (black circle) or absence (white circle) of any EPS (SAS>3) 
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Table 1. Demographic and clinical characteristics of patients with very late-onset schizophrenia-like psychosis (VLOSLP) (n=8) 
Age (years) 68  77 71  73 89 76 76 76 
Gender Female Female Female Male Female Female Female Male 
Place of birth Nigeria Cyprus Pakistan Ireland UK Greece Sri Lanka Nigeria 
Living status Alone Alone With family Alone Residential 
Care 
With husband With family Alone 
Weight (kg) 58 72 62 90 55 70 42 92 
Baseline BPRS score 13 21 19 17 18 15 20 19 
Radioactivity (MBq); Specific 
Activity (GBq/µmol); mass (µg) 
250; 100; 0.7 250; 19.1; 1.7 243; 45.9; 0.8 248; 113;0.8 247; 135;0.7 NA NA NA 
Pre-treatment prolactin (ng/ml)  3.5 5.5 8.1 5.9 5.1 - - 
Pre-treatment BPND        14.58 17.15 
 
17.94 15.56 * 16.30 NA NA NA 
Maximum dose (mg/day)  nc-  75 a 50 100 50 100 a 100b nc 
Caverage  96 41.5 102.1 69.6 172.0 114.5  
Optimum dose (mg/day) - 50 50 100 50 75 - - 
Post-treatment BPRS score - 3 4 5 7 6 3 - 
Estimated Caverage (ng/ml) 
 
- 63 41.5 102.1 70 129.3 -  
Post-treatment prolactin (ng/nl) - 50.0 82.7 92.8 163.5 89.1 - - 
Simpson Angus Score - 2 0 1 1 3 - - 
Radioactivity (MBq); Specific 
Activity (GBq/µmol); mass (µg) 
 248; 24.0; 1.8 250; 156; 0.6 - 250;179; 0.5    
Post-treatment BPND       - 8.39 9.95  6.73 ≠ - - 
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Post-treatment occupancy (%)          - 51.1 44.5 - 58.7 - - - 
 
BPRS –brief psychiatric rating scale score reflects summed total of 3 items (unusual thought content, suspiciousness, hallucinations) 
NA -not imaged due to technical diffiuclties 
≠  - unable to tolerate imaging  
a Mild extrapyramidal side effects (EPS) (SAS score 4) 
b Withdrawal from study due to hyponatraemia 
nc – non-compliant, withdrawn from study 
*Had been previously treated with olanzapine (discontinued ~ 
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Table 2.  Population Pharmacokinetic (PK) Model for Amisulpride in Older People (n=51) 
 
Parameter Estimate (RSE%) IIV% (RSE%) 
 
ka (/hr) 0.83 (18) 47 (23) 
Cl (L/hr) a, b 51.5 (7) 38 (14) 
 
V1 (L) 440 (16) 42 (25) 
Q (L/hr) 111 (16) 64 (19) 
V2 (L) 741 (12) 46 (17) 
RUV%  Estimate (RSE%)  
Healthy older people (n=20) 13 (6) na 
AD and VLOSLP (n=31) 47 (20) na 
 
Parameters: ka, absorption rate constant; V1, volume of distribution of central compartment; V2, volume 
of distribution of peripheral compartment;  Q, inter-compartmental clearance; CL, renal and systemic 
clearance 
 
 a allometric scaling (power 0.75) fixed for weight on CL; weight centred at 70kg 
 b power effect of -3.11 estimated for age on CL (p=2.3 e-008); age centred at 77 years.  
 
Other abbreviations: AD, Alzheimer’s disease; VLOSLP, very late-onset schizophrenia-like psychosis; 
IIV, inter-individual variability; RUV, residual unexplained variability; RSE, relative standard error; na, 
not applicable 
